1 d be used to better unleash the potential of
adoptive cell therapies by enhancing T cell metabolism.
2 Given their promise in
adoptive cell therapies for cancer, a deeper understandi
3 shortcomings of checkpoint blockade, such as
adoptive cell therapies.
4 IL6 is targeted as part of treatment in
adoptive cell therapy (ACT) because of its protumor effe
5 ) T cells (T(mem)) are superior mediators of
adoptive cell therapy (ACT) compared with effector CD8(+
6 ing melanoma and hematological malignancies,
adoptive cell therapy (ACT) has had only limited effects
7 Adoptive cell therapy (ACT) with tumor-specific T cells
8 Utilizing flow cytometry,
adoptive cell therapy and genetic approaches, we discove
9 ors alpha and delta improves the efficacy of
adoptive cell therapy by reprogramming T-cell metabolism
10 int to avenues for improving the efficacy of
adoptive cell therapy for cancer.
11 tocols of tumor-specific T cells followed by
adoptive cell therapy must yield T cells able to home to
12 in immunology to produce better vaccines and
adoptive cell therapy products.
13 Adoptive cell therapy represents a new paradigm in cance
14 Furthermore, in an
adoptive cell therapy treated melanoma cohort, NMD-escap
15 Adoptive cell therapy with genetically modified T cells
16 makes tTreg cells the safest cells to use in
adoptive cell therapy, increasingly used to treat autoim
17 ic malignancies and revitalized the field of
adoptive cell therapy.
18 te such cells for safer and more efficacious
adoptive cell therapy.
19 y generated T cells with higher efficacy for
adoptive cell therapy.
20 tes (TILs) for treating cancer patients with
adoptive cell therapy.
21 ediate scalable ex vivo T-cell expansion for
adoptive cell therapy.
22 , T cell expansion and persistence following
adoptive cell transfer (ACT) have correlated with superi
23 Adoptive cell transfer (ACT) is a powerful experimental
24 Adoptive cell transfer (ACT) of engineered T cell recept
25 immunotherapies, including cancer.IMPORTANCE
Adoptive cell transfer (ACT) of T cells engineered with
26 2 (IL-2) is a component of most protocols of
adoptive cell transfer (ACT) therapy for cancer, but is
27 Response to
adoptive cell transfer (ACT)-based immunotherapy in mela
28 chronically-stimulated T cells expanded for
adoptive cell transfer are susceptible to cell death in
29 In studies of bone-marrow chimeras,
adoptive cell transfer experiments, and analyses of Nemo
30 ll trafficking to the liver and spleen in an
adoptive cell transfer model.
31 and evaluated in subcutaneous xenografts and
adoptive cell transfer mouse models.
32 s including laser-Doppler perfusion imaging,
adoptive cell transfer to ischemic muscle, immunoblot an
33 ncer vaccines, immune checkpoint inhibitors,
adoptive cell transfer, and bispecific antibody therapy.
34 After
adoptive cell transfer, the CD40L(+) CAR T cells display
35 erged as an important component of effective
adoptive cell transfer-based immunotherapy for cancer.
36 engineer a wide range of cell types used in
adoptive cell transfers, including erythrocytes, macroph
37 ve as a resource for personalized vaccine or
adoptive cell-based therapy development.
38 AR-T cell therapies are the gold standard of
adoptive cellular immunotherapy for hematopoietic malign
39 clinical trials has directed interest toward
adoptive cellular therapies (ACTs).
40 ations are needed to create a wider range of
adoptive cellular therapies(1-5).
41 We demonstrate that
adoptive cellular therapy (ACT) using autologous Env-spe
42 n this fight, including checkpoint blockade,
adoptive cellular therapy and cancer vaccinology.
43 The fusion of genome engineering and
adoptive cellular therapy holds immense promise for the
44 ex vivo expanded autologous Treg cells as an
adoptive cellular therapy in renal transplant recipients
45 This study provides a general approach to
adoptive cellular therapy that can be applied to targeti
46 ugh the successes of checkpoint blockade and
adoptive cellular therapy, immunotherapy has become an e
47 process of T and B cell reconstitution after
adoptive cellular transfer.
48 While effective in specific settings,
adoptive chimeric antigen receptor (CAR) T cell therapy
49 Adoptive co-transfer experiments demonstrate a direct ef
50 (SCC) that can be effectively challenged by
adoptive cytotoxic T cell transfer (ACT)-based immunothe
51 optive parent had major depression or if the
adoptive home experienced parental death or divorce duri
52 t or stepsibling had major depression or the
adoptive home was disrupted by parental death or divorce
53 d in their home environment, those reared in
adoptive homes (homes selected in Sweden for their high-
54 in structure, despite extended enrichment in
adoptive homes in the intervening years.
55 r with in vitro colony formation and in vivo
adoptive humanized mouse transfers, indicate that eNePs
56 These insights may help elucidate future
adoptive immunotherapeutic approaches for MS patients.
57 and lymphoid cell production from hPSCs, for
adoptive immunotherapies.
58 a relevant factor in designing hPSC-derived
adoptive immunotherapies.
59 ransplantation (allo-HCT)) demonstrates that
adoptive immunotherapy can cure blood cancers: still, po
60 ination as well as for the development of an
adoptive immunotherapy for the treatment of immunocompro
61 nt of functionally competent Treg cell-based
adoptive immunotherapy in transplantation to integrate a
62 Adoptive immunotherapy using B-cell-targeted chimeric an
63 these findings provide proof of concept that
adoptive immunotherapy using ex vivo expanded CD38KO NK
64 The use of this
adoptive immunotherapy was associated with no therapy-re
65 utes to the control of many viral pathogens,
adoptive immunotherapy with virus-specific T cells (VSTs
66 ation, useful attributes for T cells used in
adoptive immunotherapy.
67 B, either through therapeutic vaccination or
adoptive immunotherapy.
68 Our results demonstrate that
adoptive MAC transfer leads to the elimination of multid
69 preclinical and clinical development such as
adoptive NK cell transfer, chimeric antigen receptor-exp
70 This protective effect disappeared if an
adoptive parent had major depression or if the adoptive
71 ctive effect of adoption disappeared when an
adoptive parent or stepsibling had major depression or t
72 ather, and adoptees and their biological and
adoptive parents.
73 ive educational status of the biological and
adoptive parents.
74 ized Th17 cells were poor inducers of EAE in
adoptive recipients.
75 regression following checkpoint blockade or
adoptive T cell immunotherapy, but are generally "privat
76 rack relevant tumor-reactive TCRs for use in
adoptive T cell immunotherapy.
77 immune surveillance against, and optimizing
adoptive T cell therapies for, gammaHV-associated lympho
78 The potency of
adoptive T cell therapies targeting the cell surface ant
79 The application of
adoptive T cell therapies, including those using chimeri
80 We recently reported the successful use of
adoptive T cell therapy (ACT) against drug-resistant/rec
81 While the outcome of
adoptive T cell therapy (ACT) is typically correlated wi
82 ion occurs in a subset of patients following
adoptive T cell therapy (ACT) of ex vivo expanded tumor-
83 Adoptive T cell therapy (ACT) using ex vivo-expanded aut
84 Adoptive T cell therapy (ACT) with genetically modified
85 ivity of both T cell checkpoint blockade and
adoptive T cell therapy as cancer immunotherapies.
86 II-restricted TCRs against NY-ESO-1 can make
adoptive T cell therapy more effective.
87 such vaccines with checkpoint inhibitors or
adoptive T cell therapy should be evaluated for possible
88 o provides a rationale for the future use of
adoptive T cell therapy targeting neoantigens in bladder
89 ce toxicity with immunotherapy, particularly
adoptive T cell therapy.
90 ells is a critical determinant of successful
adoptive T cell therapy.
91 he design of new vaccination strategies with
adoptive T cell therapy.
92 -redirected CD8+ T cells in a mouse model of
adoptive T cell therapy.
93 Using an in vivo Ag-specific
adoptive T cell transfer approach into Irf5(-/-) mice, w
94 bition sensitized immune-refractory tumor to
adoptive T cell transfer as well as PD-1 blockade, and r
95 +) virus was similar to that in WT mice, and
adoptive T cell transfer did not alter LAT RNA levels in
96 ly higher corneal scarring than WT mice, and
adoptive T cell transfer did not alter the severity of e
97 Adoptive T cell transfer experiments showed that CD137L
98 s for the success of checkpoint blockade and
adoptive T cell transfer therapies.
99 ns, such as use of checkpoint inhibitors and
adoptive T cell transfer, have shown promise but caution
100 partially but not significantly restored by
adoptive T cell transfer.
101 blockade, personal neoantigen vaccines, and
adoptive T cell transfer.
102 tential of transiently inhibiting LDH during
adoptive T cell-based immunotherapy, with an unanticipat
103 Thus, outfitting
adoptive T cells with EpoRm should yield greater effecto
104 lantation will encourage the clinical use of
adoptive T(reg) cell therapy for non-immune diseases, su
105 In
adoptive T-cell immunotherapy of cancer, expansion and p
106 TCR constitute the basis for a trial of HCC
adoptive T-cell immunotherapy.
107 rst time the clinical safety of CMV-specific
adoptive T-cell therapy and its potential therapeutic be
108 aims to provide a background on the field of
adoptive T-cell therapy and the development of genetical
109 Although
adoptive T-cell therapy has been successfully used in he
110 Although
adoptive T-cell therapy has shown remarkable clinical ef
111 More than 300
adoptive T-cell therapy trials are ongoing, which is a t
112 ceptors represent a rapidly emerging form of
adoptive T-cell therapy with the potential to overcome s
113 ches, such as immune checkpoint blockade and
adoptive T-cell therapy, boost T-cell activity against t
114 dict and elicit therapeutic responses in the
adoptive T-cell therapy.
115 potentially limit efficacy of BCMA-directed
adoptive T-cell therapy.
116 ll melanoma cells from patients resistant to
adoptive T-cell transfer (ACT) of autologous TILs.
117 The accessibility of
adoptive T-cell transfer therapies (ACT) is hindered by
118 mising candidates for nonmatched third-party
adoptive T-cell transfer with high antileukemic function
119 ection, including maribavir, letermovir, and
adoptive T-cell transfer.
120 NK cell
adoptive therapy is a promising cancer therapeutic appro
121 Adoptive therapy using chimeric antigen receptor-modifie
122 re promising alternatives to alphabeta CAR-T
adoptive therapy.
123 ific B and T lymphocytes were analyzed in an
adoptive transfer airway inflammation mouse model in res
124 izing the source of therapeutic NK cells for
adoptive transfer and enhancing NK cell cytotoxicity and
125 Using
adoptive transfer and islet transplantation models, we d
126 genetically modified (beta2-AR-/-) mice, and
adoptive transfer approaches, we found that the degree o
127 1 population in Prkdc(-/-)IL2rg(-/-) mice by
adoptive transfer drives adipose fibrogenesis through ac
128 Adoptive transfer EAE studies linked this EAE phenotype
129 trophils were found to express SAP; however,
adoptive transfer experiment supported a neutrophil-extr
130 We used
adoptive transfer experiments and studies in reporter mi
131 Adoptive transfer experiments and transcriptome analyses
132 Adoptive transfer experiments confirmed that iNKT cells
133 Consistent with cell-based data,
adoptive transfer experiments demonstrated that the anti
134 Adoptive transfer experiments demonstrated that the geno
135 Adoptive transfer experiments in mice show that modified
136 In
adoptive transfer experiments into tumor-bearing immunod
137 Adoptive transfer experiments of T(RM) cells corroborate
138 Adoptive transfer experiments revealed that intrahepatic
139 Transcriptome analyses and sequential
adoptive transfer experiments revealed that while Notch-
140 In
adoptive transfer experiments, converting apoB(+) T(regs
141 ng lymphocyte-deficient mice and a series of
adoptive transfer experiments, we demonstrate that genet
142 +) mice are pathogenic and cause ILD through
adoptive transfer experiments.
143 already expressed in thymus, as confirmed by
adoptive transfer experiments.
144 thrc1-expressing fibroblasts in in vitro and
adoptive transfer experiments.
145 After
adoptive transfer in colorectal and breast mouse tumor m
146 , and biological activity of autologous Treg
adoptive transfer in humans, we conducted an open-label,
147 we discovered a new B-cell subset that, upon
adoptive transfer into B cell-deficient mice, was suffic
148 ed proliferation of B6 T cells in vitro, and
adoptive transfer into B6 recipients 2 weeks before hete
149 it in vivo alloantibody production following
adoptive transfer into C57BL/6 or high alloantibody-prod
150 Upon
adoptive transfer into hematopoietic stem cell transplan
151 and initiate heart allograft rejection upon
adoptive transfer into mATG treated B cell deficient rec
152 airway inflammatory cell infiltration after
adoptive transfer into mice; they also increased interle
153 d in mouse Nlrp6-deficient T cells following
adoptive transfer into Rag2-deficient mice, indicating t
154 nt from naive NK cells, we performed NK cell
adoptive transfer into RAG2/cgamma-chain(-/-) mice, NK c
155 BMDC
adoptive transfer may be developed into a new approach t
156 uberculosis-infected lungs using competitive
adoptive transfer migration assays and mathematical mode
157 PLG NPs was found to prevent diabetes in an
adoptive transfer model by impairing the ability of BDC-
158 ion and less disease severity, whereas in an
adoptive transfer model of inflammatory bowel disease, t
159 Using
adoptive transfer models to compare infection-experience
160 Using
adoptive transfer models, we find that KO T regulatory c
161 Using an
adoptive transfer mouse model of IIM, we show that sarco
162 restores their ability to induce colitis in
adoptive transfer mouse models.
163 ial equation model of tumor regression after
adoptive transfer of a population of CTLs.
164 cell-directed enhancement of resolution, and
adoptive transfer of additional Tregs was sufficient to
165 ematopoietic stem cell transplantation, with
adoptive transfer of adenovirus-specific T cells being a
166 Adoptive transfer of allogeneic NK cells holds great pro
167 ls of autoimmunity and transplant rejection,
adoptive transfer of antigen-specific 3C-iTregs prevente
168 n can be effectively targeted and ablated by
adoptive transfer of antigen-specific CD8(+) T cells.
169 We show that the
adoptive transfer of B(regs) dramatically decreased the
170 Remarkably,
adoptive transfer of B-1a cells, but not splenic B cells
171 Experiments involving
adoptive transfer of bone marrow demonstrated that the m
172 Adoptive transfer of bone marrow ILC2 precursors confirm
173 Adoptive transfer of c-KIT(+) ECs into the neonatal circ
174 he combination of mild hyperthermia with the
adoptive transfer of CAR T cells can potentially increas
175 ransplantation with head shielding; and (ii)
adoptive transfer of CD115+-ACE10/GFP+ monocytes to the
176 ) animals as recipients, we demonstrate that
adoptive transfer of CD4(+) T cells alone confers marked
177 Adoptive transfer of CD4(+) T cells from PIV-vaccinated
178 2.5(mim)/calcitriol liposome administration,
adoptive transfer of CD4(+) T cells suppressed the devel
179 Survival was partially restored by
adoptive transfer of CD4(+), CD8(+), or total T cells.
180 Moreover,
adoptive transfer of CD4(+)CD45RB(high) T cells from CD8
181 Second,
adoptive transfer of CD8(+) T cells from OT1 mice to CD8
182 Furthermore, the
adoptive transfer of CD8(+) T cells from Valpha14(Tg) NC
183 validated screen hits by demonstrating that
adoptive transfer of CD8(+) T cells with Pdia3, Mgat5, E
184 Evidently,
adoptive transfer of CTLs pre-cultured with TMPs from ir
185 Adoptive transfer of DCs to mucosal sites has been limit
186 Results presented from the
adoptive transfer of encephalitogenic T cells between wi
187 Adoptive transfer of engineered T cells into patients re
188 Individualized
adoptive transfer of ex vivo expanded CMV-specific CD8+
189 In contrast,
adoptive transfer of ex vivo generated MDSC from cytokin
190 Adoptive transfer of Gas6-depleted BMM s failed to clear
191 Adoptive transfer of genetically engineered T cells expr
192 Adoptive transfer of genetically modified immune cells h
193 Furthermore, recombinant G-CSF or
adoptive transfer of granulocytic-MDSCs isolated from 4T
194 Importantly,
adoptive transfer of highly purified T(NLM) alone, from
195 ere transplanted with human skin followed by
adoptive transfer of human allogeneic splenocytes.
196 Adoptive transfer of human immunocytes from dual treated
197 Upon
adoptive transfer of human PBMC, this reductionist syste
198 cephalomyelitis (EAE), a murine model of MS,
adoptive transfer of IL-10(+) regulatory B cells (B(regs
199 Adoptive transfer of IL-10-proficient but not IL-10-defi
200 Finally, we demonstrate that
adoptive transfer of in vitro differentiated M-LECPs, bu
201 An
adoptive transfer of in vitro-generated MDSCs before or
202 sm, a phenotype that can be recapitulated by
adoptive transfer of intestinal-associated pan-B cells.
203 EAU was induced in C57BL/6 mice by
adoptive transfer of IRBP1-20-specific T cells.
204 Adoptive transfer of labeled bone marrow-derived cells v
205 Adoptive transfer of LM-MDSC into LuM resulted in a shif
206 Here, we show that
adoptive transfer of macrophages containing antimicrobia
207 Adoptive transfer of macrophages, from either collagen-t
208 Adoptive transfer of mature DCs (lipopolysaccharide [LPS
209 Adoptive transfer of mature NK cells is sufficient to de
210 Due to their strong antimicrobial activity,
adoptive transfer of MDSCs generated by in vitro culture
211 Moreover, the
adoptive transfer of memory CD8 T cells from the livers
212 Adoptive transfer of miR-214(-/-) T cells into RAG1(-/-)
213 Importantly,
adoptive transfer of mixtures of CCR2(-/-) and CCR2(+/+)
214 Importantly,
adoptive transfer of monocyte/macrophages from wild-type
215 Adoptive transfer of myeloid cells demonstrated that abe
216 We used mixed bone marrow chimeras and
adoptive transfer of naive CD4(+) T cells and Treg cells
217 te-stable gastrointestinal (GI) cancers, and
adoptive transfer of neoantigen-specific lymphocytes has
218 Adoptive transfer of neutrophils bearing LdCen(-/-) para
219 Adoptive transfer of neutrophils from beta-glucan-traine
220 Adoptive transfer of NGAL-deficient CD4(+) T cells from
221 Adoptive transfer of NK cells into NFIL3(-/-) mice befor
222 In support,
adoptive transfer of old CD4(+) T cells that were transf
223 In these mice,
adoptive transfer of ovalbumin-specific OT-I CD8 T cells
224 Intraplantar
adoptive transfer of paclitaxel-activated macrophages ev
225 wth in humanized mice generated by the human
adoptive transfer of PBMCs or the cotransplantation of h
226 ial infection (cecal ligature and puncture),
adoptive transfer of Pink1-deficient bone marrow or phar
227 Adoptive transfer of Pmel-1 x SLAMF6 -/- T cells to mela
228 unction of individual T cell clones, and the
adoptive transfer of protective effector or regulatory T
229 Adoptive transfer of PTPN2-deficient CD8(+) T cells mark
230 Here we show that the
adoptive transfer of purified IgG from convalescent rhes
231 Adoptive transfer of purified immunoglobulin G (IgG) fro
232 Adoptive transfer of recoverin-stimulated cells into nai
233 mental and preclinical evidence suggest that
adoptive transfer of regulatory T (Treg) cells could be
234 Adoptive transfer of sera containing anti-donor MHC clas
235 Adoptive transfer of splenic T cells into NOD.Rag1(-/-)
236 As a result,
adoptive transfer of such IL-15-addicted NK cells is ass
237 Adoptive transfer of T cell expressing this public alpha
238 In comparison to
adoptive transfer of T cell progenitors, BMCs increased
239 Adoptive transfer of T cell receptor-engineered (TCR-eng
240 Finally,
adoptive transfer of T cells containing IL-6Ra(-/-) Treg
241 The
adoptive transfer of T cells expressing chimeric antigen
242 Immunotherapy with the
adoptive transfer of T cells redirected with CD19-specif
243 Adoptive transfer of T cells that express a chimeric ant
244 Adoptive transfer of T cells that express a chimeric ant
245 Adoptive transfer of T(C)2 cells differentiated under hy
246 Adoptive transfer of Th17 cells to naive mice is suffici
247 Adoptive transfer of these three MDSCs led to differenti
248 Adoptive transfer of these tumor-specific cells signific
249 The effects of
adoptive transfer of transplant (tx), tumor (tm), and gr
250 bound after withdrawal of treatments, and by
adoptive transfer of treated lymphocytes into uninfected
251 In EAE-induced female mice,
adoptive transfer of Treg cells and spinal delivery of t
252 Adoptive transfer of Tregs enhanced this CL activity.
253 Adoptive transfer of TSG6- or IL-4-primed BMM s i.t.
254 Adoptive transfer of tumor antigen-experienced T cells e
255 Adoptive transfer of tumor epitope-reactive T cells has
256 al to the success of checkpoint blockade and
adoptive transfer of tumor-infiltrating lymphocyte (TIL)
257 ng an immune response against cancer through
adoptive transfer of tumor-targeting lymphocytes has sho
258 lated autologous tumor cells followed by the
adoptive transfer of vaccine-primed lymphocytes after AS
259 vation, in vivo pre clinical PAD models, and
adoptive transfer of VEGF(165)b-expressing bone marrow-d
260 Moreover,
adoptive transfer of virus-specific effector CD8(+) T ce
261 Adoptive transfer of virus-specific T cells has proven t
262 hat in the wild-type mice and was rescued by
adoptive transfer of wild-type B-1 cells.
263 Adoptive transfer of wild-type T cells did not alter sur
264 lymphoid organs, and this can be restored by
adoptive transfer of wild-type T cells or administration
265 In parallel,
adoptive transfer of WT neutrophils into Par4(-/-) mice
266 CD4(+) T-cell depletion studies or the
adoptive transfer of WT OVA-specific CD4(+) T cells to W
267 Conversely,
adoptive transfer or purified donor-strain nT-regs inhib
268 dition of the LAG-3-blocking antibody to the
adoptive transfer protocol improved the SLAMF6 -/- T cel
269 male mice with pre-established obesity, Treg
adoptive transfer reduced the gWAT weight in 2 weeks.
270 Together with CL treatment, Treg
adoptive transfer reduced the SAT weight and further imp
271 ivity of these cells both in vitro and in an
adoptive transfer SCID model of pulmonary fibrosis.
272 We applied cell depletion and
adoptive transfer strategies using lymphocyte-deficient
273 Adoptive transfer studies demonstrated T cell intrinsic
274 dies has not previously been demonstrated in
adoptive transfer studies in nonhuman primates.
275 Bone marrow chimera and
adoptive transfer studies indicate that these memory T c
276 Rather, data from
adoptive transfer studies suggested that defective accum
277 Adoptive transfer studies using mice lacking beta2AR (be
278 Adoptive transfer studies were performed with Tc1 clones
279 ed through depletion (anti-CD4 antibody) and
adoptive transfer studies.
280 oduction by T cells and exacerbated EAE upon
adoptive transfer than did wild-type DCs.
281 ta) T cells exhibit longer persistence after
adoptive transfer than do CD28-costimulated CAR (28zeta)
282 preclinical and clinical development include
adoptive transfer therapies, direct stimulation, recruit
283 B cell
adoptive transfer to mice reduced infarct volumes 3 and
284 ry, ELISA, RNA sequencing, quantitative PCR,
adoptive transfer to mice, and measurement of airway hyp
285 of allergic airway inflammation, and T-cell
adoptive transfer to recombination-activating gene 1 (Ra
286 nd conditional deletion of TSLP receptor and
adoptive transfer were used to identify the cellular sub
287 n sulfate sodium, Mdr1a(-/-), and CD45RB(hi)
adoptive transfer).
288 Through
adoptive transfer, CD8(+) lung T cells but not CD4(+) T
289 G-3+/TNF-alphalow CD8 T cells and, following
adoptive transfer, the rapid expression of exhaustion ma
290 Using
adoptive transfer, we demonstrate that PI3Kgamma is impo
291 Using a genetic approach complemented by
adoptive transfer, we found that neutrophils are essenti
292 In conclusion, the BMDC
adoptive transfer-induced immunogenic tolerance in OVA-s
293 bonucleoprotein immediately prior to in vivo
adoptive transfer.
294 and attenuated Con A-induced hepatitis upon
adoptive transfer.
295 (TCR) may achieve cure of HBV infection upon
adoptive transfer.
296 t promoted curative antitumor immunity after
adoptive transfer.
297 n of functional CAR effector cells following
adoptive transfer.
298 triggering robust antitumor responses after
adoptive transfer.
299 In an
adoptive-
transfer mouse model of type-1 diabetes, treatm
300 Adoptive transfers with several types of immune cells or